Conference Coverage
Latest News
Jan 04, 2026 | Commentary
Uncovering the Complex Relationship Between ADHD and Epilepsy Surgery Outcomes
A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines
Jan 04, 2026
NeurologyLive® Brain Games: January 4, 2025
Jan 04, 2026
Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS
Jan 03, 2026
Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026
Jan 02, 2026
Advertisement
Shorts
Media-Driven Misconceptions of Narcolepsy
25 days ago
by
Julie Flygare, JD(+1 more)
0:30
Barriers to Early Diagnosis and Access to Care in MS
a month ago
by
Ethel Ciampi, MD, MSc(+1 more)
1:30
Collaboration Within the ALS Community
2 months ago
by
Jinsy A. Andrews, MD, MSc(+1 more)
1:30
Safety Considerations for Kygevvi in Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Data Backing First Treatment for Tk2d
2 months ago
by
Fabian Somers, PhD(+1 more)
1:30
Training the Next Neuromuscular Specialists
2 months ago
by
John Norbury, MD(+1 more)
1:15
Evolving Landscape of Myasthenia Gravis Treatment
2 months ago
by
Leila Darki, MD(+1 more)
1:05
Aerobic Exercise and Promoting Remyelination in MS
2 months ago
by
Lindsey Wooliscroft, MD, MS(+1 more)
1:12
MDS 2025: Learning From Progress in Other Disease States
3 months ago
by
Lorraine Kalia, MD, PhD(+1 more)
1:16
MDS 2025: Biologically Defining Parkinson Disease
3 months ago
by
Tanya Simuni, MD, FAAN(+1 more)
Coverage of AANEM 2025
Get direct access to interviews with experts, straight from the conference floor in San Francisco, as well as the latest data and clinical news updates.
Mind Moments Podcast
Mind Moments® is a biweekly podcast from NeurologyLive that brings you exclusive interviews with expert neurologists and clinicians.
DAMM Good Sleep
Check out DAMM Good Sleep × NeurologyLive for neurology-focused sleep content to allow any neurology stakeholder to use sleep as the diagnostic, prognostic, and therapeutic neurology tool it should be.
NeuroVoices
NeuroVoices is NeurologyLive's series of in-depth, exclusive Q&A conversations with a variety of experts in the care and management of patients with neurologic diseases about topics in clinical care and therapeutic development.
Gold Standard Centers
Gold Standard Centers is our deep dive feature series on examples of institutional success in neurologic medicine, highlighting the centers that are leading the way in care.
Videos
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.
As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.
Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.
Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.
At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.
As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.
These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.
NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.
Advertisement
Here's some of what is coming soon to NeurologyLive® this week.
Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment
Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!
In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.
Apazunersen, an investigational intrathecal therapy, is being evaluated in the phase 3 Aspire trial for pediatric Angelman syndrome, with study completion anticipated in the second half of 2026.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Previewing Expected FDA Decisions in Neurology for 2026
2
Clinical Perspectives on Promising Phase 1 Data of CAPN2-Targeting Therapy AMX0114 for ALS
3
Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026
4
NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care?
5